ArticleEuropean journal of rheumatology2026
Libman-Sacks Endocarditis in Triple-Positive Antiphospholipid Syndrome Following Switch from Warfarin to Rivaroxaban: Improvement After Reinstitution of Warfarin and Escalation of Immunosuppression.
Article in European journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-positive antiphospholipid syndrome (APS) represents a high-risk serologic phenotype associated with recurrent thrombosis and systemic lupus erythematosus (SLE). Direct oral anticoagulants (DOACs), particularly rivaroxaban, have demonstrated inferior outcomes compared with vitamin K antagonists in this population. We report a case of a patient with long-standing SLE and persistently triple-positive APS who developed Libman-Sacks endocarditis following a switch from warfarin to rivaroxaban. The patient had biopsy-proven class V lupus nephritis and had remained clinically stable on long-term warfarin therapy for several years. Transthoracic echocardiography demonstrated underlying rheumatic mitral valve disease with newly developed mobile vegetations measuring 10-15 mm. Blood cultures obtained prior to antibiotic exposure were negative, and inflammatory markers were not suggestive of infection. Rivaroxaban was discontinued, and warfarin was reinstated with bridging therapy. Prednisolone (40 mg daily) was initiated, and follow-up echocardiography demonstrated a reduction in vegetation size with clinical improvement. This case highlights a temporal association between rivaroxaban use and valvular thrombotic lesions in high-risk APS. Improvement was likely multifactorial, reflecting combined effects of anticoagulation, escalation of immunosuppression, and underlying valvular disease. These findings support current recommendations favoring vitamin K antagonists over DOACs in patients with triple-positive APS. Cite this article as: Saleh I, Salman S, Alkady A, Saqabi FA. Libman-Sacks endocarditis in triple-positive antiphospholipid syndrome following switch from warfarin to rivaroxaban: improvement after reinstitution of warfarin and escalation of immunosuppression. Eur J Rheumatol. 2026, 13(2), 0009, doi: 10.5152/ eurjrheum.2026.26009.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.